List view / Grid view
Packaging
Aptar Pharma extends nasal pump manufacturing capabilities
Aptar Pharma has announced the installation of manufacturing capacity for its child-resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.
Does the Falsified Medicines Directive lead to a European pack coding guideline?
The Directive on Falsified Medicines (FMD, or Directive 2011/62/EU amending Directive 2001/83/EC) and its supplementing Delegated Regulation (DR 2016/161) aim to improve patient safety by preventing falsified medicines from entering the legal supply chain...
Strategic aspects of change control for pharmaceutical packaging systems
Plastic materials used in pharmaceutical packaging can interact with the packaged dosage form, causing leachables to accumulate...
FMD and supply chain security
Over 12 months ago, the European Union delegated regulation that supplements the Falsified Medicines Directive (FMD) was published in the Official Journal of the European Union, starting the countdown to the deadline of 9 February 2019, when most EU member-states, and three non-members currently, are expected to have implemented all…
Issue #2 2017 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
Packaging In-Depth Focus 2017
FMD and supply chain security; Strategic aspects of change control for pharmaceutical packaging systems; and does the Falsified Medicines Directive lead to a European pack coding guideline?
ESP & GS1 Ireland Partner to Improve Biopharmaceutical Anti-Counterfeiting Solutions
28 October 2016 | By ESP
Enterprise System Partners (ESP) has formally signed a partnership agreement with GS1 Ireland to work collaboratively in the development and delivery of the highest anti-counterfeiting solutions based on GS1 standards to the biopharmaceutical manufacturing industry...
ESP GS1 Ireland Serialisation Industry Readiness Report 2016
28 October 2016 | By ESP
In collaboration with our partners GS1 Ireland, ESP carried out an extensive industry survey to establish the status of the industry in relation to the impending serialisation deadlines, which are facing us in the coming months and years...
Issue #3 2016 – Digital edition
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...
Pharmaceutical Packaging In-Depth Focus 2016
In this Pharmaceutical Packaging In-Depth Focus: End-to-end verification of the medicines supply chain; Understanding the financial implications of the upcoming falsified medicines regulations; Point of view on the evolution of labelling and packaging.
Pharmapack Europe launches new Start-up Hub
31 May 2016 | By Pharmapack
Pharmapack is a two-day exhibition and conference dedicated to pharmaceutical packaging, drug delivery and affiliated industries...
PAT for packaging: review of applications for expeditious, nondestructive quality testing
15 April 2014 | By Jose Montenegro-Alvarado, Bradley Diehl, Jean-Maxime Guay, Steve Hammond, Hiwot Isaac, Ben Lyons, Conor McSweeney, Seamus O’Neill, Jean-Sébastien Simard and Joep Timmermans, Pfizer Inc.
This article reviews some emerging applications of Process Analytical Technologies (PAT) for packaging quality testing. Specifically, four commercially-available packaging applications are explored in further detail: Raman spectroscopy for rapid material identification testing of polymeric packaging materials; vision-based elastic deformation for non-destructive blister integrity testing; X-ray monitoring for inline blister fill…
Innovation showcase at CPhI Awards 2013
25 October 2013 | By Dr Kevin Robinson
It doesn’t seem to matter what the industry is or, indeed, what the event is these days, the same question pops up at regular intervals: where’s the innovation? I’m happy to report that innovation is very much alive and well in the pharmaceutical industry and was on show to the…
New guidelines for breakmarks on tablets
13 June 2013 | By Tony Moffat, UCL School of Pharmacy and Joint Pharmaceutical Analysis Group
The US Food and Drugs Administration (FDA) produced their guidance for industry on tablet scoring in March 2013 to ensure that tablet scoring (breakmarks or breaklines) on generic tablets would enable them to be split in the same effective way as their reference listed products (RLD).